Cargando…
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study
A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid, theobromine, (T-1-PCPA). At first, we started wi...
Autores principales: | Eissa, Ibrahim H., Yousef, Reda G., Elkady, Hazem, Alsfouk, Aisha A., Alsfouk, Bshra A., Husein, Dalal Z., Ibrahim, Ibrahim M., Elkaeed, Eslam B., Metwaly, Ahmed M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867533/ https://www.ncbi.nlm.nih.gov/pubmed/36676140 http://dx.doi.org/10.3390/life13010191 |
Ejemplares similares
-
New Anticancer Theobromine Derivative Targeting EGFR(WT) and EGFR(T790M): Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies
por: Elkaeed, Eslam B., et al.
Publicado: (2022) -
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach
por: Eissa, Ibrahim H., et al.
Publicado: (2023) -
A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies
por: Eissa, Ibrahim H., et al.
Publicado: (2023) -
Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer
por: Eissa, Ibrahim H, et al.
Publicado: (2023) -
Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
por: Eissa, Ibrahim H., et al.
Publicado: (2023)